SCHEMBL24630635

SCHEMBL24630635

CN(C)n1ccc2ccc(C(C)(C)C)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.40
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 3/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MCL1 Q07820 1/20 0.33
SLC6A2 P23975 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32
RECQL P46063 1/20 0.32
KMT2A Q03164 1/20 0.32
EPHX2 P34913 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23482162 0.83 KCNH2 (0.36) KCNH2CYP1A2CYP2C19ALDH1A1HPGD
SCHEMBL2627060 0.76 CYP2A6 (0.50) KCNH2ALDH1A1HPGDALOX15HSD17B10
SCHEMBL30046333 0.76 CYP2A6 (0.50) KCNH2ALDH1A1HPGDALOX15HSD17B10
SCHEMBL6629489 0.74 KMO (0.41) CYP1A2ALDH1A1HPGDHSD17B10SLC6A2
SCHEMBL6629531 0.74 SLC6A2 (0.46) ALDH1A1SLC6A2KDM4EMEN1MAPT
SCHEMBL16589295 0.74 KCNH2 (0.41) KCNH2CYP1A2CYP2C19ALDH1A1HPGD
SCHEMBL20353866 0.71 HTR7 (0.44) KCNH2MCL1EPHX2NR1H4HTR7
SCHEMBL19910557 0.71 KCNH2 (0.40) KCNH2ALDH1A1HPGDALOX15HSD17B10
SCHEMBL6626507 0.70 KDM4E (0.43) CYP1A2ALDH1A1HPGDHSD17B10SLC6A2
SCHEMBL8957563 0.69 NOTUM (0.54) KCNH2ALDH1A1HPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220378743-A1 METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2022-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220378743-A1 METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS SLC10A1, CYP7A1, FABP1 KCNH2 4488/4885CYP1A2 89/4885CYP2C19 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.